ImmunityBio stock

IBRX · NASDAQ · USD

Compare ImmunityBio
$6.04Change from previous close: +0.25%Absolute change: +$0.02

Close · November 16, 2026

Price history

+197.29% over the period

1 year: from $2.03 (November 17, 2025) to $6.04 (November 16, 2026), +197.29%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$6.04
October 30, 2026$8.29
September 30, 2026$9.44
August 31, 2026$7.95
July 31, 2026$7.17
June 30, 2026$8.76
May 29, 2026$7.52
April 30, 2026$7.10
March 31, 2026$7.67
February 27, 2026$9.78
January 30, 2026$6.25
December 31, 2025$1.98
November 28, 2025$2.36
November 17, 2025$2.03

At a glance

  • The company

    Biotechnology company developing next-generation immunotherapies to activate the immune system against cancer and infectious diseases

  • Latest results

    Quarter to September 30, 2026 · EPS -$0.09 (estimate -$0.08)

TickerLandia's take on ImmunityBio

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$1.95
52-wk high$12.43

−51.45% from the 52-week high

Analysts · 4 analysts

Average target$14.25+136.12% vs. price

Buy 4 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: ImmunityBio

Compared with similar companies: very low earnings stability, very high growth, and very high risk.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

How ImmunityBio is valued

Compared with 11 similar companies

ImmunityBio's metrics compared with similar companies
MetricImmunityBioPosition in the groupBand
Operating margin-150.2%Low
ROE122.9%High
Debt/equity-1.17Low
Net margin0.0%Middle
Price/sales35.1High

Grey band: the middle half of the group; tick: the median; dot: ImmunityBio. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$51.24M

Latest quarter · Q2 2026

Net income

-$230.38M

Latest quarter · Q2 2026

Quarterly net margin

-449.6%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$6.4B
EPS
-$1.06
Volume
13.3M
Daily trading
€92.87M
Dividend yield
0.00%

How ImmunityBio is changing

All results
  • Revenue grew 184.8% a year on average over the last 5 years

  • Operating margin rose from −146,374.2% to −226.0%

  • Shares outstanding up 144.0% in 5 years

Returns

ImmunityBio returns

$1,000 invested in ImmunityBio 5 years ago, on November 16, 2021, would be worth $854 today: −14.64% in total, −3.12% per year. This is the price return only: dividends are excluded.

PeriodImmunityBioS&P 500$1,000 becomes
1 month−34.26%−3.12%$657
6 months−24.28%+2.07%$757
Year to date+204.80%+10.46%$3,048
1 year+197.29%+13.33%$2,973
3 years+47.56%+67.73%$1,476
5 years−14.64%+60.86%$854
10 years−21.52%+247.35%$785

Over the last 6 months it has done better than 6% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

ImmunityBio: technical analysis

ImmunityBio shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 85.7% below its all-time closing high ($42.25, February 22, 2021).

Trend
No clear trend
RSI (14 sessions)
33
Between 30 and 70
vs 200-session average
−24.27%

Support and resistance

Price areas where ImmunityBio has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$8.48+40.44%7 touches, last on September 28, 2026
  2. Resistance$7.72+27.92%3 touches, last on October 26, 2026
  3. Resistance$6.68+10.69%5 touches, last on July 28, 2026
  4. Last price$6.04
  5. Support$5.56−7.87%2 touches, last on February 5, 2026
  6. Support$2.48−58.91%2 touches, last on December 12, 2025
  7. Support$1.98−67.27%2 touches, last on December 31, 2025

Volatility and risk

Over the last year it has moved more than the S&P 500.

Beta (1 year) vs S&P 500
1.52
Volatility (60 sessions, annualised)
86.6%
Largest fall in the last year
−47.88%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

ImmunityBio: seasonality

Average monthly price change over 12 years

+21.9%Jan+7.6%Feb−9.6%Mar+1.3%Apr+5.5%May+13.5%Jun−4.3%Jul−9.2%Aug−1.5%Sep+1.7%Oct+12.2%Nov+4.9%Dec

Over the last 12 years, the strongest month for ImmunityBio has been January: +21.92% on average, positive in 4 years out of 11. The weakest has been March: −9.59% on average, positive in 3 years out of 11. November, the current month, has been positive in 7 years out of 11 (+12.19% on average).

Show chart data
MonthAverageMedianPositive years
January+21.92%−4.28%4 of 11
February+7.57%+0.45%6 of 11
March−9.59%−17.98%3 of 11
April+1.29%−7.43%5 of 11
May+5.45%−1.13%5 of 11
June+13.53%−0.97%4 of 11
July−4.30%−8.96%4 of 11
August−9.19%−4.22%4 of 12
September−1.51%−4.42%5 of 12
October+1.72%−7.31%5 of 12
November+12.19%+6.06%7 of 11
December+4.90%−8.37%4 of 11

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

ImmunityBio and its competitors

Headquartered in San Diego, California, and in existence since 2014, ImmunityBio develops immunotherapies meant to strengthen the body's own immune response against cancer and infectious diseases. Its development platforms cover fusion proteins built on cytokines, DNA-based and viral vector vaccines, and cell therapies, and its clinical programs address both liquid and solid tumors. Its lead product, Anktiva, holds FDA approval and is used alongside BCG in adults with bladder cancer that no longer responds to BCG, a non-muscle invasive form that includes carcinoma in situ.

Headquarters
San Diego, United States
Employees
684
Founded
2014
Chief executive
Richard Adcock
ImmunityBio and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
ImmunityBioIBRX$6.4B-150.2%—−24.28%
Twist BioscienceTWST$7.4B-28.8%—+113.09%
Corcept TherapeuticsCORT$9.36B0.8%190.2+22.80%
Madrigal PharmaceuticalsMDGL$9.93B-10.7%—−18.72%
BioMarin PharmaceuticalBMRN$11.09B16.3%146.8+12.23%
Summit TherapeuticsSMMT$11.32B0.0%—−28.81%

Same industry or related industries, similar size. Compare ImmunityBio with its competitors · Full profile